Spero Therapeutics (NASDAQ:SPRO) Posts Earnings Results, Beats Expectations By $0.73 EPS

Spero Therapeutics (NASDAQ:SPRO) posted its earnings results on Thursday. The company reported $0.53 EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.73, FiscalAI reports. Spero Therapeutics had a negative return on equity of 125.91% and a negative net margin of 108.11%.The company had revenue of $41.30 million for the quarter, compared to the consensus estimate of $26.00 million.

Spero Therapeutics Trading Down 1.7%

Shares of NASDAQ SPRO opened at $2.37 on Friday. Spero Therapeutics has a 12-month low of $0.51 and a 12-month high of $3.22. The firm’s 50-day moving average price is $2.36 and its 200-day moving average price is $2.30. The stock has a market capitalization of $133.52 million, a price-to-earnings ratio of -3.00 and a beta of 1.45.

Insider Buying and Selling

In other Spero Therapeutics news, insider Esther Rajavelu sold 87,917 shares of the business’s stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $2.36, for a total transaction of $207,484.12. Following the sale, the insider directly owned 1,012,091 shares of the company’s stock, valued at $2,388,534.76. The trade was a 7.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of SPRO. XTX Topco Ltd purchased a new position in Spero Therapeutics during the 2nd quarter worth $100,000. Invesco Ltd. purchased a new stake in shares of Spero Therapeutics in the 2nd quarter worth $43,000. Vanguard Group Inc. lifted its holdings in shares of Spero Therapeutics by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,989,855 shares of the company’s stock worth $3,741,000 after buying an additional 39,474 shares during the period. Dimensional Fund Advisors LP bought a new position in shares of Spero Therapeutics during the 3rd quarter worth $55,000. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of Spero Therapeutics during the 3rd quarter worth $283,000. Hedge funds and other institutional investors own 25.60% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on SPRO. Wall Street Zen downgraded Spero Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, March 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Spero Therapeutics in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Spero Therapeutics presently has a consensus rating of “Reduce”.

About Spero Therapeutics

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.